Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKE18W)

• Drug Name: Methionine Sulfoxide Drug Info
• Synonyms: Methionine sulfoxide; DL-Methionine sulfoxide; methionine sulfoxide; 62697-73-8; 454-41-1; dl-methioninesulfoxide; 2-Amino-4-(methylsulfinyl)butanoic acid; Uethionine, S-oxide; Methionine, S-oxide; Butanoic acid, 2-amino-4-(methylsulfinyl)-; 2-Amino-4-(methylsulfinyl)butyric acid; H-DL-Met(O)-OH; 2-amino-4-methanesulfinylbutanoic acid; BUTYRIC ACID, 2-AMINO-4-(METHYLSULFINYL)-; SQ 2292; 2-Amino-4-(methylsulphinyl)butyric acid; MFCD00002620; S-OXYMETHIONINE; (1)-2-Amino-4-(methylsulphinyl)butyric acid; 4241-59-2; methioninsulfoxid; S-Oxymethionine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 847
  ChEBI ID: CHEBI:49033
  CAS Number: CAS 62697-73-8
  TTD Drug ID: DMKE18W

Molecule-Related Drug Atlas

Drug(s) Targeting Candida Thymidylate synthase (Candi TMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[2]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[3]
Pemetrexed	DMMX2E6	Central nervous system lymphoma	2B33.5	Approved	[4]
Trifluridine	DMG2YBD	Herpetic keratitis	1F00.10	Approved	[5]
Capecitabine	DMTS85L	Adenocarcinoma	2D40	Approved	[6]
Raltitrexed	DMT9K8G	Rectal adenocarcinoma	2B92	Approved	[7]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[8]
Flucytosine	DM13VTW	Cryptococcal meningitis		Approved	[9]
Nolatrexed	DMOF0CA	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
Plevitrexed (R)-isomer	DMTL39C	Gastric adenocarcinoma	2B72	Phase 2	[11]

Drug(s) Targeting Amyloid beta A4 protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nirogacestat	DMUP5Z0	Desmoid tumour	2F7C	Approved	[12]
Aducanumab	DM51JW4	Alzheimer disease	8A20	Approved	[13]
Lecanemab	DMW03YD	Alzheimer disease	8A20	Approved	[14]
Florbetapir F-18	DMJ8A3Z	Diagnostic imaging	N.A.	Approved	[15]
GV-971	DMTMA5W	Alzheimer disease	8A20	Approved in China	[16]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
Solanezumab	DM0HIU5	Alzheimer disease	8A20	Phase 3	[18]
Tramiprosate	DM7BSRH	Alzheimer disease	8A20	Phase 3	[19]
Bapineuzumab	DMHQ5GK	Alzheimer disease	8A20	Phase 3	[20]
ALZT-OP1	DMG5BTD	Alzheimer disease	8A20	Phase 3	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amyloid beta A4 protein (APP)	TTE4KHA	A4_HUMAN	Inhibitor	[1]
Candida Thymidylate synthase (Candi TMP1)	TTU6BFZ	TYSY_CANAL	Inhibitor	[1]

References

• [1] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [2] The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
• [3] Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
• [4] Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
• [5] Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
• [6] UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
• [7] DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
• [8] Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
• [9] Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
• [10] A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
• [11] Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
• [14] The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [16] Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.
• [17] Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
• [18] Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
• [19] Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
• [20] Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)